Drug maker Lupin Monday said it has received approval from the US health regulator for Clobazam Oral Suspension, used to treat seizures associated with Lennox-Gastaut Syndrome.
The company has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Lundbeck Pharmaceuticals LLC's Onfi Oral Suspension, Lupin said in a regulatory filing.
The drug is indicated for treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients of two years of age or older.
Clobazam Oral Suspension (2.5 mg/ml) had annual sales of around USD 260.2 million in the US.
Lupin shares Monday ended 0.78 per cent up at Rs 845.60 apiece on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
